Compare EARN & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | ENLV |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 149.0M |
| IPO Year | 2012 | 2014 |
| Metric | EARN | ENLV |
|---|---|---|
| Price | $4.41 | $1.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.38 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 409.0K | 310.9K |
| Earning Date | 06-16-2026 | 05-29-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.69 | N/A |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $0.43 |
| 52 Week High | $5.89 | $7.64 |
| Indicator | EARN | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 36.93 |
| Support Level | $4.29 | $0.70 |
| Resistance Level | $4.48 | $1.81 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 78.26 | 10.34 |
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.